Online inquiry

IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9010MR)

This product GTTS-WQ9010MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Asthma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9010MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7684MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ9014MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ12389MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NEOD-001
GTTS-WQ13956MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ12489MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ15786MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ9131MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ10420MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2439821
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW